课题基金 / 基金详情

Engineering immunomodulatory exosomes derived from human mesenchymal stem cells for treatment of acute inflammatory conditions

Engineering immunomodulatory exosomes derived from human mesenchymal stem cells for treatment of acute inflammatory conditions
工程化源自人间充质干细胞的免疫调节外泌体用于治疗急性炎症
批准号:
376393
负责人:
Tieu Alvin
金额:
$10.93万
依托单位:
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-11-01 至 2020-11-01

项目摘要

项目成果

Tieu Alvin的其他基金

相似基金

相关文献

中文摘要
翻译
急性呼吸窘迫综合征(ARDS)和败血症是加拿大的主要死亡原因,特别是对于危重患者。这些破坏性疾病的特征是对损伤或感染的严重炎症反应。在
英文摘要
Acute respiratory distress syndrome (ARDS) and sepsis are among the leading causes of death in Canada, especially for critically ill patients. These devastating conditions are characterized by severe inflammation in response to an insult or infection. In
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunomodulatory exosomes derived from human mesenchymal stem cells for treatment of acute and chronic pulmonary vascular conditions
Immunomodulatory exosomes derived from human mesenchymal stem cells for treatment of acute respiratory distress syndrome
Engineering immunomodulatory exosomes derived from human mesenchymal stem cells for treatment of acute inflammatory conditions
  • 批准号:
    383405
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $7.65万
  • 财政年份:
    2017
  • 负责人:
    Tieu Alvin
  • 依托单位:
Beta Blocker Effectiveness in Hemodialysis Patients
  • 批准号:
    331351
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $1.27万
  • 财政年份:
    2014
  • 负责人:
    Tieu Alvin
  • 依托单位:
海外基金